RxDoctor Payments Data

Teresa Greiner, MD

Psychiatry · Angola, INNPI 1003834128

Payments from drug & device makers

$5,641in general payments, 2019–2025

Across 310 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$979
  • Alkermes, Inc.$668
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$529
  • Sunovion Pharmaceuticals Inc.$462
  • Neurocrine Biosciences, Inc.$433
  • Johnson & Johnson$359
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$5,52398%
  • Education$1182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,641 in reported general payments places this provider in the 85th percentile of 514 psychiatry providers in Indiana.

See all psychiatry providers in Indiana

Medicare billing

Part B allowed, 2024
$16,935
Medicare patients
68
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$210,086
CaplytaLumateperone Tosylate106$168,854
VraylarCariprazine Hcl72$101,651
FanaptIloperidone24$80,842
RexultiBrexpiprazole51$68,462
Abilify MaintenaAripiprazole26$66,497
AuvelityDextromethorphan Hbr/Bupropion39$33,241
TrintellixVortioxetine Hydrobromide35$25,931
BelsomraSuvorexant37$16,376
FetzimaLevomilnacipran Hcl18$13,812
Clozapine OdtClozapine21$12,405
Paliperidone ErPaliperidone24$6,616
Vilazodone Hcl70$6,567
Lurasidone Hcl55$6,021
Atomoxetine Hcl59$6,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$433$210,08623 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$529$168,854106 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$979$134,95977 claims
AbbVieVraylar, Fetzima$266$115,46490 claims
Vanda Pharmaceuticals Inc.Fanapt$91$80,84224 claims
Axsome Therapeutics, Inc.Auvelity$276$33,24139 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$30$30,70047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 514 psychiatry providers in Indiana.

Other psychiatry in Angola

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →